Sialic Acid Conjugate-Modified Cationic Liposomal Paclitaxel for Targeted Therapy of Lung Metastasis in Breast Cancer: What a Difference the Cation Content Makes
Molecular Pharmaceutics · 2024
DOI: 10.1021/acs.molpharmaceut.3c00767 ↗Kurz gefasst
Fachartikel in der Zeitschrift Molecular Pharmaceutics, 2024. Verfasst von Wenliang Sun und 10 weiteren Autor:innen. Beteiligte Einrichtung: College of Pharmacy, Shenyang Pharmaceutical University, Shenyang 110016, China. Hauptthemen laut MEDLINE: Breast Neoplasms, Lung Neoplasms. Die Arbeit wurde bisher 4-mal zitiert (Crossref) und nennt 57 Literaturangaben. Gefördert von: National Natural Science Foundation of China.
Abstract (Originalsprache)
Cationic lipids play a pivotal role in developing novel drug delivery systems for diverse biomedical applications, owing to the success of mRNA vaccines against COVID-19 and the Phase III antitumor agent EndoTAG-1. However, the therapeutic potential of these positively charged liposomes is limited by dose-dependent toxicity. While an increased content of cationic lipids in the formulation can enhance the uptake and cytotoxicity toward tumor-associated cells, it is crucial to balance these advantages with the associated toxic side effects. In this work, we synthesized the cationic lipid HC-Y-2 and incorporated it into sialic acid (SA)-modified cationic liposomes loaded with paclitaxel to target tumor-associated immune cells efficiently. The SA-modified cationic liposomes exhibited enhanced binding affinity toward both RAW264.7 cells and 4T1 tumor cells in vitro due to the increased ratios of cationic HC-Y-2 content while effectively inhibiting 4T1 cell lung metastasis in vivo. By leveraging electrostatic forces and ligand-receptor interactions, the SA-modified cationic liposomes specifically target malignant tumor-associated immune cells such as tumor-associated macrophages (TAMs), reduce the proportion of cationic lipids in the formulation, and achieve dual objectives: high cellular uptake and potent antitumor efficacy. These findings highlight the potential advantages of this innovative approach utilizing cationic liposomes.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- College of Pharmacy, Shenyang Pharmaceutical University, Shenyang 110016, China.
- Wuya College of Innovation, Shenyang Pharmaceutical University, Shenyang l10016, China.
- Key Laboratory of Structure-Based Drug Design & Discovery of Ministry of Education, School of Pharmaceutical Engineering, Shenyang Pharmaceutical University, Shenyang 110016, China.
- Department of Pharmacy, Faculty of Health and Medical Sciences, University of Copenhagen, Universitetsparken 2, DK-2100 Copenhagen, Denmark.
ORCID-Profile: Yanzhi Song, Mingshi Yang, Guoliang Chen, Yihui Deng
Förderung
- National Natural Science Foundation of China
Zitieren
APA
Sun, W., Han, C., Ge, R., Jiang, X., Wang, Y., Han, Y., Wang, N., Song, Y., Yang, M., Chen, G., & Deng, Y. (2024). Sialic Acid Conjugate-Modified Cationic Liposomal Paclitaxel for Targeted Therapy of Lung Metastasis in Breast Cancer: What a Difference the Cation Content Makes. Molecular Pharmaceutics. https://doi.org/10.1021/acs.molpharmaceut.3c00767
Vancouver
Sun W, Han C, Ge R, Jiang X, Wang Y, Han Y, et al. Sialic Acid Conjugate-Modified Cationic Liposomal Paclitaxel for Targeted Therapy of Lung Metastasis in Breast Cancer: What a Difference the Cation Content Makes. Molecular Pharmaceutics. 2024. doi:10.1021/acs.molpharmaceut.3c00767
BibTeX
@article{Sun2024,
author = {Sun, Wenliang and Han, Chao and Ge, Ruirui and Jiang, Xiaotong and Wang, Yu and Han, Yingchao and Wang, Ning and Song, Yanzhi and Yang, Mingshi and Chen, Guoliang and Deng, Yihui},
title = {Sialic Acid Conjugate-Modified Cationic Liposomal Paclitaxel for Targeted Therapy of Lung Metastasis in Breast Cancer: What a Difference the Cation Content Makes},
journal = {Molecular Pharmaceutics},
year = {2024},
doi = {10.1021/acs.molpharmaceut.3c00767}
}
EUVIMED